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Abstract
Introduction Estrogen deprivation using aromatase inhibitors is
one of the standard treatments for postmenopausal women with
estrogen receptor (ER)-positive breast cancer. However, one of
the consequences of prolonged estrogen suppression is
acquired drug resistance. Our group is interested in studying
antihormone resistance and has previously reported the
development of an estrogen deprived human breast cancer cell
line, MCF-7:5C, which undergoes apoptosis in the presence of
estradiol. In contrast, another estrogen deprived cell line, MCF-
7:2A, appears to have elevated levels of glutathione (GSH) and
is resistant to estradiol-induced apoptosis. In the present study,
we evaluated whether buthionine sulfoximine (BSO), a potent
inhibitor of glutathione (GSH) synthesis, is capable of
sensitizing antihormone resistant MCF-7:2A cells to estradiol-
induced apoptosis.
Methods Estrogen deprived MCF-7:2A cells were treated with
1 nM 17β-estradiol (E2), 100 μM BSO, or 1 nM E2 + 100 μM
BSO combination in vitro, and the effects of these agents on
cell growth and apoptosis were evaluated by DNA quantitation
assay and annexin V and terminal deoxynucleotidyl transferase
dUTP nick end-labeling (TUNEL) staining. The in vitro results of
the MCF-7:2A cell line were further confirmed in vivo in a mouse
xenograft model.
Results Exposure of MCF-7:2A cells to 1 nM E2 plus 100 μM
BSO combination for 48 to 96 h produced a sevenfold increase
in apoptosis whereas the individual treatments had no
significant effect on growth. Induction of apoptosis by the
combination treatment of E2  plus BSO was evidenced by
changes in Bcl-2 and Bax expression. The combination
treatment also markedly increased phosphorylated c-Jun N-
terminal kinase (JNK) levels in MCF-7:2A cells and blockade of
the JNK pathway attenuated the apoptotic effect of E2 plus
BSO. Our in vitro findings corroborated in vivo data from a
mouse xenograft model in which daily administration of BSO
either as a single agent or in combination with E2 significantly
reduced tumor growth of MCF-7:2A cells.
Conclusions Our data indicates that GSH participates in
retarding apoptosis in antihormone-resistant human breast
cancer cells and that depletion of this molecule by BSO may be
critical in predisposing resistant cells to E2-induced apoptotic
cell death. We suggest that these data may form the basis of
improving therapeutic strategies for the treatment of
antihormone resistant ER-positive breast cancer.
Introduction
Currently, estrogen deprivation using aromatase inhibitors is
one of the standard treatments for postmenopausal women
with estrogen receptor (ER)-positive breast cancer [1]. Unfor-
tunately, a major clinical problem with the use of prolonged
estrogen deprivation is the development of drug resistance
(that is, hormone-independent growth) [2,3]. Our laboratory as
well as other investigators, have instigated a major effort in
BSO: L-buthionine sulfoximine; E2: 17β-estradiol; ER: estrogen receptor; FBS: fetal bovine serum; GCS: glutamylcysteine; GPx2: glutathione perox-
idase; GS: glutathione synthetase; GSH: glutathione; H&E: hematoxylin and eosin; JNK: c-Jun N-terminal kinase; Rh123: rhodamine 123; SFS: dex-
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studying antihormone resistance in breast cancer and have
developed model systems of estrogen deprivation that are
sensitive [4-6] or resistant to the apoptotic actions of estrogen
[7]. In particular, we have previously reported the development
of an estrogen deprived breast cancer cell line, MCF-7:5C,
which undergoes estradiol-induced apoptosis after 2 days of
treatment via the mitochondrial pathway [8]. In contrast, we
have another estrogen deprived breast cancer cell line, MCF-
7:2A, which appears to be resistant to estradiol-induced
apoptosis [7]. We are studying resistance to estrogen
induced apoptosis because clinical experience shows us that
only 30% of patients respond to estrogen induced apoptosis
once exhaustive antihormonal therapy occurs [9]. An impor-
tant goal would be to see whether the apoptotic effect of
estrogen can be enhanced in antihormone resistant cells. This
new, targeted approach to the treatment of metastatic breast
cancer could open the door to novel approaches to treatment
with drug combinations.
L-Buthionine sulfoximine (BSO) is a specific γ-glutamyl-
cysteine synthetase inhibitor that blocks the rate-limiting step
of glutathionine (GSH) biosynthesis and in doing so depletes
the intracellular GSH pool in both cultured cells and in whole
animals [10]. GSH is a water-soluble tripeptide composed of
glutamine, cysteine, and glycine. Reduced glutathione is the
most abundant intracellular small molecule thiol present in
mammalian cells and it serves as a potent intracellular antioxi-
dant protecting cells from toxins such free radicals [11,12].
Changes in GSH homeostasis have been implicated in the eti-
ology and progression of a variety of human diseases, includ-
ing breast cancer [13]. In particular, studies have shown that
elevated levels of GSH prevent apoptotic cell death whereas
depletion of GSH facilitates apoptosis [10,14]. BSO depletes
cellular GSH [10] and sensitizes tumor cells to apoptosis
induced by standard chemotherapeutic agents [15,16].
Apoptosis (programmed cell death) is required for normal
development and tissue homeostasis in multicellular organ-
isms. Deregulation of apoptosis is fundamental to many dis-
eases, such as cancer, stroke, heart disease,
neurodegenerative disorders, and autoimmune disorders [17].
There are two main pathways for apoptosis, namely the extrin-
sic receptor mediated pathway and the intrinsic mitochondria-
mediated pathway [18,19]. Components of the extrinsic path-
way include the death receptors FasR/FasL, DR4/DR5, and
tumor necrosis factor (TNF) [20], whereas the intrinsic path-
way centers on the Bcl-2 family of proteins which comprises
both proapoptotic proteins, such as Bax, Bak, and Bid and
antiapoptotic proteins, such as Bcl-2 and Bcl-xL [18,19]. The
Bcl-2 family proteins regulate apoptosis by altering mitochon-
drial membrane permeabilization which leads to the release of
apoptogenic factors such as cytochrome c, procaspases, and
apoptosis inducing factor (AIF). In particular, Bcl-2 and Bcl-xL
inhibit apoptosis by maintaining mitochondrial membrane
integrity whereas Bax and Bak facilitate apoptosis by initiating
the loss of outer mitochondrial integrity [21]. Apart from its
action on the mitochondria, there is also evidence that Bcl-2
possesses antioxidant property. Bcl-2 overexpression
increases cellular GSH level which is associated with
increased resistance to chemotherapy-induced apoptosis
[22,23] whereas GSH depletion restores apoptosis in Bcl-2
expressing cells [16].
Based on microarray studies we found that the antihormone
resistant MCF-7:2A cells express markedly elevated levels of
glutathione synthetase (GS) and glutathione peroxidase 2
(GPx2); two enzymes that are involved in glutathione synthe-
sis, which suggests that resistance to estrogen-induced apop-
tosis might be due to elevated levels of GSH present in the
cells. If MCF-7:2A cells do indeed possess high levels of
GSH, then it is possible that the use of BSO – as a single
agent – might be able to sensitize these cells to estrogen-
induced apoptosis. As mentioned before, there is current clin-
ical interest in using low dose estradiol therapy to treat antihor-
mone resistant breast cancer [24] however only a minimal
30% of patients respond to this therapeutic strategy. A com-
bination of BSO and estradiol could possibly be used to
improve the efficacy of estradiol as an apoptotic agent if glu-
tathione depletion is fundamental to tumor cell survival. We
have addressed the hypothesis that by altering glutathione lev-
els we may be able to enhance apoptosis to estrogen and
have employed BSO as our agent of choice because of earlier
work clinically, which may provide a foundation for subsequent
clinical trials.
In the present study, we show that depletion of cellular GSH
by BSO sensitizes antihormone-resistant MCF-7:2A cells to
estradiol-induced apoptosis that is mediated, in part, by the
mitochondrial pathway and also activation of the c-Jun N-ter-
minal kinase (JNK) signaling pathway. We further show that
BSO, either alone or in combination with estradiol, causes
tumor regression of MCF-7:2A cells in vivo.
Materials and methods
Cell lines and reagents
The MCF-7 human breast cancer cell line was obtained from
Dr Dean Edwards (University of Texas, San Antonio, TX, USA)
and was maintained in phenol red RPMI 1640 medium supple-
mented with 10% fetal bovine serum (FBS), 2 mM glutamine,
100 U/mL penicillin, 100 μg/mL streptomycin, 1 × non-essen-
tial amino acids and bovine insulin at 6 ng/mL. The clonal cell
line, MCF-7:2A, was derived by growing MCF-7 cells in estro-
gen-free media for more than 1 year, followed by two rounds
of limiting dilution cloning [7]. These cells were grown in phe-
nol red-free RPMI 1640 medium supplemented with 10% 4 ×
dextran-coated, charcoal-treated FBS (SFS). All reagents for
cell culture were obtained from Invitrogen (Life Technologies,
Carlsbad, CA, USA). DL-Buthionine sulfoximine (BSO) and
17β-estradiol (E2) were from Sigma (St Louis, MO, USA),
rhodamine 123 (Rh123) was from Invitrogen (Life Technoli-Available online http://breast-cancer-research.com/content/10/6/R104
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gies, Carlsbad, CA, USA). LY294002 and SP600125 were
from EMD (Gibbstown, NJ, USA)
Western blot analysis
The antibodies used for western blotting included those
against stress-activated protein kinase (SAPK)/JNK, phospho-
SAPK/JNK (Thr183/Tyr185), caspase-7, caspase-9, phos-
pho-Bcl-2 (Ser70), and poly(ADP-ribose) polymerase (PARP)
(Cell Signaling Technology, Danvers, MA, USA), cytochrome
c and β-actin (Sigma, St Louis, MO, USA), cytochrome oxi-
dase subunit IV (Cox IV; Invitrogen, Carlsbad, CA, USA), Bax,
Bcl-2, and Bcl-xL (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Western blotting analysis was performed as previously
described [8].
Cell proliferation assays
Proliferation assay was performed as previously described [8].
Briefly, MCF-7 and MCF-7:2A cells were seeded in estrogen-
free RPMI media containing 10% SFS at a density of 2 × 104
cells per well in 24-well plates. After 24 h, cells were treated
with the respective drugs for 2, 5, and 7 days with retreatment
on alternate days. The DNA content of the cells was deter-
mined as previously described [25] using a Fluorescent DNA
Quantitation kit (Bio-Rad, Hercules, CA, USA). For each anal-
ysis, six replicate wells were used, and at least three independ-
ent experiments were performed.
Cell proliferation was also determined by cell counting using a
hemocytometer. MCF-7 and MCF-7:2A cells were seeded at
a density of 0.5 × 106 cells in 100 mm dishes and after 24 h
cells were treated with 1 nM E2, 100 μM BSO, or 1 nM E2 plus
100 μM BSO for 7 days with re-treatment on alternate days.
For each analysis, three replicate dishes were used, and at
least three independent experiments were performed.
Detection of apoptosis by annexin V staining
The annexin V-fluorescein isothiocyanate (FITC) labeled Apop-
tosis Detection Kit I (BD Biosciences, San Jose, CA, USA)
was used to detect and quantify apoptosis by flow cytometry,
according to the manufacturer's instructions.
Terminal deoxynucleotidyl transferase-mediated dUTP 
nick end-labeling (TUNEL) staining for apoptosis
Apoptosis was also determined by the TUNEL assay using an
in situ cell death detection kit conjugated with horse-radish
peroxidase (POD) (Roche Applied Science, Indianapolis, IN,
USA), according to the manufacturer's instructions. Briefly,
fixed cells were washed, permeabilized, and then incubated
with 50 μL of terminal deoxynucleotidyl transferase end-labe-
ling cocktail for 60 min at 37°C in a humidified atmosphere in
the dark. For signal conversion, slides were incubated with 50
μL of converter-POD (anti-fluorescein antibody conjugated
with horseradish peroxidase) for 30 min at 37°C, rinsed with
PBS, and then incubated with 50 μL of 3,3'-diaminobenzidine
(DAB) substrate solution for 10 min at 25°C. The slides were
then rinsed with phosphate-buffered saline (PBS), mounted
under glass coverslips, and analyzed under a light microscope
using an inverted Nikon TE300 (Nikon, Melville, NY, USA).
GSH assay
Total cellular GSH was measured using the Total Glutathione
Colorimetric microplate assay Kit (Oxford Biomedical
Research), according to the manufacturer's protocol. Cells
were plated at 0.5 × 106/well of a six-well plate and allowed to
recover overnight. After appropriate treatments, cells were
washed in PBS and then lysed in 100 to 150 μl of buffer (100
mM NaPO4, 1 mM ethylenediaminetetraacetic acid (EDTA),
pH 7.5) containing 0.1% Triton X-100 and frozen at -80°C
until analysis. To measure total glutathione, proteins were pre-
cipitated with sulfosalicylic acid at a final concentration of 1%.
Samples were then spun for 10 min in a microcentrifuge to
pellet proteins, and supernatant was diluted 1:20 in buffer
before being measured. For all measurements, 50-μl tripli-
cates of each sample were used for glutathione determination.
The GSH level was obtained by comparing with the GSH
standards and represented as nmol/mg of protein.
Mitochondrial transmembrane potential (ΔΨm) and 
cytochrome c release
Changes in the mitochondrial membrane potential (ΔΨm)
were examined by monitoring the cells after staining with rhod-
amine 123. Briefly, estradiol plus BSO-treated MCF-7:2A
cells were washed twice with PBS and incubated with 1 μg/
mL rhodamine 123 at 37°C for 30 min. Cells were then
washed twice with PBS, and Rh123 intensity was determined
by flow cytometry. Cells with reduced fluorescence were
counted as having lost some of their mitochondrial membrane
potential.
For cytochrome c  release assays, cells were lysed in lysis
buffer (10 mmol/L N-2-hydroxyethylpiperazine-N'-2-ethanesul-
fonic acid (HEPES; pH 7.5), 10 mmol/L KCl, and 1 mmol/L
EDTA) with protease inhibitor cocktail (Sigma), frozen and
thawed three times, and centrifuged at 2,000 g for 5 min. The
supernatants were centrifuged at 10,000 g for 15 min at 4°C,
and the mitochondrial pellets were dissolved in sodium
dodecyl sulfate (SDS) sample buffer, subjected to 15% SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), and ana-
lyzed by immunoblotting with monoclonal antibodies against
cytochrome c and Cox IV.
RNA isolation and quantitative real-time polymerase 
chain reaction (PCR)
Total RNA was isolated using TRI reagent (Invitrogen) accord-
ing to the manufacturer's protocol. RNA (2 μg) was reverse
transcribed to cDNA using the SuperScript II RNase H-
reverse transcriptase system (Invitrogen, Carlsbad, CA, USA).
Aliquots of the cDNA were combined with the SYBR green kit
and primers, and assayed in triplicate by real-time quantitative
PCR using a GeneAmp® 5700 Sequence detection systemBreast Cancer Research    Vol 10 No 6    Lewis-Wambi et al.
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(Applied Biosystems Inc, Foster City, CA, USA). Quantitation
was performed using the comparative threshold cycle (Ct)
method with 18S rRNA as the normalization gene, as previ-
ously described [8]. GS and GPx2 primers were designed
using Primer Express™ software following the manufacturer's
guidelines. Primers were synthesized by Applied Biosystems.
Quantitative PCR was performed using the following condi-
tions: 40 cycles; denaturation at 95 C for 15 s, annealing at 63
C for 1 min, and polymerization at 72 C for 1 min. Primer
sequences were: GS forward: CACCAGCT GGGGAAG-
CATCT; reverse: GGTGAGGGGAAGAGCGT GAA, GPx2
forward: TTG ATT AAG GCT TTC TTT GGT AGG; reverse:
TTT CAA TAA ATC AGG TCC CAG G.
Small interfering RNA (siRNA) transfection
Bcl-2-specific siRNA was chemically synthesized by Dhar-
macon Inc (Chicago, IL, USA). A non-targeting siRNA duplex
was used as negative control. For transfection, MCF-7:2A
cells were seeded in complete medium without antibiotics the
day before the experiment in 12-well plates at a density of
70,000 cells per well. After 24 h, cells were transfected with
100 nM of Bcl-2 siRNA or control siRNA, using DharmaFect 1
transfection reagent (Dharmacon Inc, Chicago, IL, USA),
according to the manufacturer's protocol. The cells were har-
vested 48 h post transfection and analyzed by western blot.
Transfected cells were also treated with estradiol for an addi-
tional 72 h and apoptotic cells were measured using annexin
V staining.
Inhibition of MCF-7:2A cell tumorigenesis by BSO in 
nude mice
Female CrTac:NCr-Foxn1nu athymic mice (4 to 5 weeks old)
were purchased from Taconic (Germantown, NY, USA). Ani-
mal experiments were conducted at the Fox Chase Cancer
Center (Philadelphia, PA, USA). The research protocol was
approved, and mice were maintained in accordance with insti-
tutional guidelines of the Fox Chase Cancer Center Animal
Care and Use Committee. Mice were acclimatized to the ani-
mal facility for 1 week before they received injections of MCF-
7:2A human breast cancer cells: 2 × 107 cells were resus-
pended in 100 μL PBS (Collaborative Biomedical Products,
Bedford, MA, USA) and were bilaterally injected into the mam-
mary fat pads of 20 ovariectomized mice. Tumors were
allowed to develop for 20 days until they reached a mean
cross-sectional area of 0.32 cm2, when treatment was initiated
with placebo (saline), E2 (0.3 cm capsule), BSO (4 mmol/kg
weight), or BSO (4 mmol/kg weight) plus E2 (0.3 cm capsule)
for an additional 7 days. For the estradiol treatment, 0.3 cm
silastic estradiol capsules (Baxter HealthCare, Mundeleine, IL,
USA) were implanted subcutaneously in the mice. These cap-
sules produced a mean serum estradiol level of 83.8 pg/mL
[26], to achieve postmenopausal serum levels of estradiol.
BSO was dissolved in saline and was administered intraperi-
toneally daily for 7 days. The cross-sectional tumor area was
calculated by multiplying the length (l) by the width (w) by π
and dividing the product by 4 (lwπ/4). Animals were given food
and water ad libitum. Mice from each group (n = 5) were killed
at the conclusion of the experiment and immunohistochemical
analysis was performed.
Tissue preparation and immunohistochemistry
Tumors from mice treated with placebo, E2, BSO, or BSO plus
E2 were excised and fixed in 10% formalin, embedded in par-
affin wax blocks and sectioned. Subsequently, sections of the
tumor blocks were stained with hematoxylin and eosin (H&E),
Ki67, or PARP antibody (1:500 dilution, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) by the pathology core facility at
Fox Chase Cancer Center.
Statistical analysis
Statistical analysis was performed using the Student t test,
and a p value of < 0.05 was considered significant. Data are
expressed as the mean ± standard error of the mean (SEM).
The mean value was obtained from at least three independent
experiments.
Results
Estrogen deprivation increases glutathione levels in 
MCF-7:2A breast cancer cells
Elevated glutathione levels and the activity of its related
enzymes have been characterized as one of the factors which
could render breast cancer cells resistant to apoptosis. We
have previously shown that MCF-7:2A breast cancer cells are
resistant to estrogen-induced apoptosis [7], therefore we
measured glutathione levels in these cells along with parental
MCF-7 cells. Figure 1a showed that glutathione levels were
significantly higher in MCF-7:2A cells (11.9 μM/mg protein)
compared to MCF-7 cells (7.8 μM/mg protein) and treatment
with BSO (100 μM), an inhibitor of glutathione synthesis, for
24 h depleted glutathione content by approximately 55% and
68% in MCF-7 and MCF-7:2A cells, respectively. It is worth
noting that glutathione levels were consistently elevated in
MCF-7:2A cells up to 7 days and the inhibitory effect of BSO
persisted throughout that incubation period (Figure 1a, insert).
We next examined whether the expression of glutathione-
related enzymes was altered in these cells. Using quantitative
real-time PCR, we found a 6-fold increase in glutathione syn-
thetase (GS) expression and a 40-fold increase in glutathione
peroxidase 2 (GPx2) expressions in MCF-7:2A cells com-
pared to parental MCF-7 cells (Figure 1b). Western blot anal-
ysis also showed a marked increase in GS protein level in
MCF-7:2A cells compared to parental MCF-7 cells (Figure 1b,
right panel).
BSO enhances the apoptotic effect of E2 in MCF-7:2A 
cells
We next examined whether depletion of glutathione levels by
BSO sensitizes MCF-7:2A cells to estrogen-induced apopto-
sis. For proliferation assays, MCF-7 and MCF-7:2A cells wereAvailable online http://breast-cancer-research.com/content/10/6/R104
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seeded in estrogen-free media, and after 24 h, were treated
with 100 μM BSO, 1 nM E2, or 100 μM BSO plus 1 nM estra-
diol for 2, 5, and 7 days. Figure 2a shows that the growth of
parental MCF-7 cells was stimulated sevenfold over the con-
trol cells by 1 nM estradiol during the course of the 7-day
assay and that treatment with BSO, either alone or in combi-
nation with estradiol, did not significantly alter the growth of
these cells. In contrast, MCF-7:2A cells treated with the com-
bination of 100 μM BSO and 1 nM estradiol showed a signif-
icant time-dependent decrease in cell growth relative to cells
treated with either estradiol or BSO alone. The growth inhibi-
tory effect of BSO and estradiol was observed as early as 48
h after treatment and persisted over the time course of the
experiment with maximum cell death at the 7-day time point.
The combination of estradiol plus BSO also significantly
reduced the proliferation of MCF-7:2A cells (Fig. 2c, bottom)
but it did not affect the growth of wild type MCF-7 cells (Figure
2c, top). Furthermore, we found that treatment with the anties-
trogen 4-hydroxytamoxifen (4-OHT) almost completely
reversed the growth inhibitory effect of estradiol and BSO in
MCF-7:2A cells (see Additional data file 1) which suggests
the involvement of the ER in this process.
Based on the above finding, we next determined whether
MCF-7:2A cells underwent apoptotic cell death upon BSO
and estradiol treatment. We performed a TUNEL assay, which
detects the fragmentation of DNA, which is characteristic of
cells undergoing apoptotic cell death. As shown in Figure 3a,
the percentage of TUNEL-positive cells significantly increased
with the combination of BSO and estradiol but not with estra-
diol or BSO alone. After treatment with BSO and estradiol (96
h), as many as 53% of cells displayed TUNEL-positive stain-
ing, whereas, only 1% of the control cells and 5% of the estra-
diol-treated cells were TUNEL-positive. BSO-treated cells
Figure 1
Intracellular glutathione (GSH) levels in wild-type MCF-7 cells and antihormone-resistant MCF-7:2A breast cancer cells Intracellular glutathione (GSH) levels in wild-type MCF-7 cells and antihormone-resistant MCF-7:2A breast cancer cells. (a) MCF-7 and MCF-7:2A 
cells were seeded at 2 × 106 cells per 100 mm culture plates in phenol red RPMI media containing 10% fetal bovine serum (FBS) and phenol red-
free RPMI media containing 10% 4× dextran coated charcoal-treated FBS (SFS), respectively, and after 24 h were treated with nothing (control) 
(white columns) or 100 μM buthionine sulfoximine (BSO) (black columns) for 24 h. Total cellular glutathione was measured using a Glutathione 
Colorimetric microplate assay kit, as described in Materials and methods. Columns, mean from three separate experiments; bars, ± standard error of 
the mean (SEM). **, p < 0.001 compared with control cells; #, p < 0.05 compared with MCF-7 control cells. Insert graph shows glutathione levels in 
MCF-7:2A cells over a 7-day period. (b) Quantitative real-time polymerase chain reaction (PCR) of glutathione sythetase (GS) (top left) and glutath-
ione peroxidase 2 (GPx2) (bottom left) mRNA expression in MCF-7 and MCF-7:2A cells. **, p < 0.001 compared with MCF-7 control cells. Western 
blot analysis of GS protein expression in MCF-7:2A cells is also shown (top right).Breast Cancer Research    Vol 10 No 6    Lewis-Wambi et al.
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looked similar to control cells. As expected, parental MCF-7
cells showed very little TUNEL-positive staining in the pres-
ence of estradiol alone or BSO plus estradiol combined (Fig-
ure 2b, top panel), thus indicating a lack of apoptosis in these
cells.
To further substantiate the apoptotic effect of BSO and estra-
diol in MCF-7:2A cells, annexin V-PI immunostaining was per-
formed by flow cytometry. Figure 3b shows that in the BSO
plus estradiol-treated group, approximately 55.6% of cells
stained positive for annexin V whereas in the control group and
estradiol-treated group, approximately 7.4% and approxi-
mately 15.6%, respectively, of cells stained positive for
annexin V. For the BSO-treated group, only 8.7% of cells
stained positive for annexin.
Role of the mitochondrial pathway in BSO plus estradiol-
induced apoptosis in MCF-7:2A cells
To examine the role of the mitochondrial pathway in BSO plus
estradiol-induced apoptosis, western blot analyses was used
to measure Bax, Bcl-2, phosphorylated Bcl-2, and Bcl-xL pro-
tein levels in MCF-7:2A cells following treatment with 1 nM
estradiol alone, 100 μM BSO, or BSO plus estradiol for 48 h.
We found that Bcl-2, phospho-Bcl-2, and Bcl-xL protein levels
were almost completely reduced in MCF-7:2A cells treated
with BSO plus estradiol compared to control, BSO, or estra-
diol alone. In addition, a marked increase in Bax expression
was also observed in MCF-7:2A cells following BSO plus
estradiol combined treatment (Figure 4a). In contrast, similar
experiments performed with parental MCF-7 cells showed that
BSO plus estradiol slightly increased Bcl-2 and phospho-Bcl-
2 protein levels in these cells with a more dramatic effect
observed with estradiol alone (Figure 4a). It is worth noting
that in MCF-7:2A cells endogenous levels of Bcl-2 and phos-
phorylated Bcl-2 were markedly elevated compared to paren-
tal MCF-7 cells. This finding is consistent with previous reports
which show that overexpression of Bcl-2 increases glutath-
ione levels and inhibits mitochondrial dysfunction and cell
death elicited by glutathione-depleting reagents [27].
Although estradiol, as an individual treatment, did not signifi-
cantly induce apoptosis in MCF-7:2A cells, it did decrease
Bcl-2 protein level in these cells. We therefore tested whether
siRNA knockdown of Bcl-2 expression would sensitize MCF-
7:2A cells to estradiol-induced apoptosis. Expression of Bcl-2
following knockdown was analyzed by western blotting. As
expected, Bcl-2 protein levels were significantly reduced fol-
lowing transfection of MCF-7:2A cells with Bcl-2 siRNA com-
Figure 2
Effect of buthionine sulfoximine (BSO) plus estradiol on the growth of wild-type MCF-7 cells and antihormone-resistant MCF-7:2A cells Effect of buthionine sulfoximine (BSO) plus estradiol on the growth of wild-type MCF-7 cells and antihormone-resistant MCF-7:2A cells. (a) MCF-7 
cells were grown in estrogen-free media for 3 days prior to the start of the growth assay. On the day of the experiment, 30,000 cells were seeded in 
24-well plates and after 24 h were treated with < 0.1% ethanol vehicle (control), 1 nM 17β-estradiol (E2), 100 μM BSO, or 100 μM BSO plus 1 nM 
E2 for 7 days. At the indicated time points, cells were harvested and total DNA (ng/well) was quantitated as described in Materials and methods. The 
data represent the mean of three independent experiments; bars, ± standard error of the mean (SEM). **, p < 0.001 compared with control cells. (b) 
MCF-7:2A cells were seeded at the same density as MCF-7 cells and were treated similarly. The data represent the mean of three independent 
experiments; bars, ± SEM. **, p < 0.001 compared with control cells; ##, p < 0.001 compared with estradiol-treated cells. (c) The effect of BSO 
plus estradiol on cell proliferation was also determined by cell counting using a hemocytometer. For experiment, 0.5 × 106 MCF-7 (top) and MCF-
7:2A (bottom) cells were seeded in 15-cm dishes and after 24 h were treated with 1 nM estradiol, 100 μM BSO, or E2 plus BSO combination for 7 
days. Data shown represents the mean of three independent experiments; bars, ± SEM. **, p < 0.001 compared with control cells; ##, p < 0.001 
compared with estradiol-treated cells.Available online http://breast-cancer-research.com/content/10/6/R104
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pared to control siRNA (Figure 4b, top panel). Using annexin
V staining, we found that apoptosis was increased by 20% in
Bcl-2 siRNA transfected cells compared with cells transfected
with the control siRNA (Figure 4b, bottom panel), thus sug-
gesting that suppression of antiapoptotic factors such as Bcl-
2 has the ability to partially sensitize hormone-independent
MCF-7:2A cells to apoptosis.
We next examined mitochondrial membrane integrity using the
Rh123 retention assay. Cells were treated with nothing (con-
trol), estradiol, BSO, or BSO plus estradiol for 48 h. Figure 4c
shows that BSO plus estradiol treatment reduced Rh123 flu-
orescence in MCF-7:2A cells by approximately 50% com-
pared to control, whereas, estradiol or BSO, as individual
treatments, did not significantly alter Rh123 retention levels in
these cells. BSO plus estradiol also enhanced cytochrome c
release in MCF-7:2A cells. Figure 4d shows that in the control
cells, cytochrome c was detected primarily in the mitochondria
and was undetectable in the cytosol; however, in the presence
of BSO plus estradiol (48 h), all of cytochrome c  was
observed in the cytosol. BSO or estradiol, as individual treat-
ments, did not significantly alter mitochondrial release of cyto-
chrome  c. The translocation of cytochrome c  from the
mitochondria to the cytosol following BSO plus estradiol treat-
ment coincided with cleavage of caspase 7 and PARP (Figure
4e), which is a molecular signature of apoptosis. Cleavage of
PARP and caspase 7 was blocked by the pan-caspase inhibi-
tor z-VAD (data not shown).
The apoptotic effect of BSO and estradiol in MCF-7:2A 
cells is regulated, in part, by JNK signaling
Emerging evidence supports a role for JNK in stress-induced
mitochondrial apoptotic pathways in a variety of cell systems
[28]. Therefore, we examined the possible involvement of c-
Jun/JNK pathway in BSO plus estradiol-induced apoptosis in
MCF-7:2A cells. JNK activation was determined by western
Figure 3
Buthionine sulfoximine (BSO) plus estradiol induce apoptosis in MCF-7:2A cells Buthionine sulfoximine (BSO) plus estradiol induce apoptosis in MCF-7:2A cells. (a) Terminal deoxynucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL) staining for apoptosis in MCF-7:2A cells following BSO plus 17β-estradiol (E2) treatment for 96 h were performed as described in 
Materials and methods. Slides were photographed through a brightfield microscope under 100 × magnification. TUNEL-positive cells were stained 
black (white arrows). Columns (right), mean percentage of apoptotic cells (annexin V-positive cells) from three independent experiments performed 
in triplicate; bars, ± standard error of the mean (SEM). *, p < 0.001 compared with control cells; #, p < 0.001 compared with estradiol-treated cells. 
(b) Annexin V staining for apoptosis. Cells were seeded in 100 mm plates at a density of 1 × 106 per plate and after 24 h were treated with ethanol 
vehicle (control), 1 nM E2, or BSO plus E2 for 72 h and then stained with fluorescein isothiocyanate (FITC)-annexin V and propidium iodide (PI) and 
analyzed by flow cytometry. PI was used as a cell viability marker. Representative cytograms are shown for each group. Quantitation of apoptosis 
(percentage of control) in the different treatment groups is shown on the right. bars, ± SEM. *, p < 0.05 compared with control cells; #, p < 0.01 
compared with estradiol-treated cells.Breast Cancer Research    Vol 10 No 6    Lewis-Wambi et al.
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blot analysis after 48-h treatment of cells with BSO plus estra-
diol. A profound induction of the p54 and p46 isoforms of
phosphorylated JNK as well as a significant increase in phos-
pho-c-Jun and c-Jun were observed in MCF-7:2A cells treated
with BSO plus estradiol compared to BSO alone or control
(Figure 5a). Interestingly, treatment with estradiol alone also
significantly increased phosphorylated JNK in MCF-7:2A cells.
We also found that pretreatment of MCF-7:2A cells with the
JNK inhibitor, SP600125 (20 μM) markedly reduced the apop-
totic effect of BSO plus estradiol in these cells (Figure 5b).
Overall, these results suggest a possible involvement of the c-
Jun/JNK signaling pathway in BSO plus estradiol-induced
apoptosis in MCF-7:2A cells.
BSO inhibits the growth of MCF-7:2A cells in vivo
To determine whether the effect of BSO plus estradiol was rel-
evant in vivo, we used a xenograft model in which MCF-7:2A
cells were injected into CrTac:NCr-Foxn1nu athymic mice (n =
20). At 20 days post injection, tumors grew to a mean cross-
sectional area of 0.30 cm2 and mice were randomized to four
groups; placebo (saline), estradiol, BSO, or the combination
of BSO plus estradiol, as described in materials and methods.
After 7 days of treatment, tumor growth was reduced by 25%
in mice treated with estradiol alone whereas in the BSO and
BSO plus estradiol group tumor growth was reduced by 40%
and 60%, respectively, compared to the placebo group which
showed a 7% increase in growth (Figure 6a). Interestingly, we
Figure 4
Effect of buthionine sulfoximine (BSO) and 17β-estradiol (E2) on Bcl-2 family protein expression and mitochondrial function in MCF-7 and MCF-7:2A  cells Effect of buthionine sulfoximine (BSO) and 17β-estradiol (E2) on Bcl-2 family protein expression and mitochondrial function in MCF-7 and MCF-7:2A 
cells. (a) Western blot analysis for pBcl-2, Bcl-2, Bcl-xL, and Bax protein expression in parental MCF-7 cells and MCF-7:2A cells following 48 h of 
treatment with ethanol vehicle (Control), 1 nM E2, 100 μM BSO, or E2 + BSO. Equal loading was confirmed by reprobing with an antibody against 
β-actin. (b) Small interfering RNA (siRNA) knockdown of Bcl-2 partially sensitizes MCF-7:2A cells to E2-induced apoptosis. Cells were transfected 
with 100 nM siRNA-Bcl-2 or siRNA-Con (control) and expression levels of Bcl-2 was determined by immunoblot analysis (top). Annexin V staining 
(bottom) showing the effects of siRNA-con and siRNA-Bcl-2 on apoptosis induced by estradiol treatment in MCF-7:2A cells. *, p < 0.001. (c) Loss 
of mitochondrial potential in MCF-7:2A cells was determined by rhodamine 123 (Rh123) retention assay. The percentage of cells retaining Rh123 in 
each treatment group was compared with untreated control. (d) Cytochrome c release from the mitochondria to the cytosol after treatment with E2 
alone or BSO and E2 for 48 h was determined as described in Materials and methods. Anti-Cox IV antibody was used as a control to demonstrate 
that mitochondrial protein fractionation was successfully achieved. (e) Cleavage of caspase 7 and poly(ADP-ribose) polymerase (PARP) (72 h) was 
assessed by western blot using specific antibodies. The upper band of caspase 7 represents the full-length protein and the lower band (p20, arrow) 
represents the cleaved activated product; NS, nonspecific. Full length PARP is approximately 116 kDa; cleaved (active) PARP is 85 kDa (arrow). 
The results are representative of three independent experiments.Available online http://breast-cancer-research.com/content/10/6/R104
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found that BSO in vitro had a relatively small effect on growth,
however, in vivo its effect was very pronounced, thus suggest-
ing the possibility of altered glutathione metabolism in vivo.
We performed histology on tumors taken from placebo, estra-
diol, BSO, or BSO plus estradiol groups at day 27. H&E stain-
ing of the BSO plus estradiol-treated tumors revealed less
tumor cells and more intercellular matrix, significantly less
mitoses, chromatin clumping and dark staining which are
associated with apoptosis, and enhanced abnormalities in
shape and size, compared to tumors from placebo or BSO or
estradiol-treated groups (Figure 6b). We also characterized
the proliferative status of these cells by staining tumors for the
expression of Ki67, a marker of cell proliferation. We observed
a 32% decrease (p < 0.001) in the number of Ki67 stained
tumors from the BSO plus estradiol-treated group and a 21%
decrease in the BSO-treated group compared to the placebo
group whereas estradiol treatment caused an 8% increase in
Ki67 staining (Figure 6c). Immunohistochemistry of paraffin-
embedded tumor sections of mice treated with the combina-
tion of BSO and estradiol showed increased immunostaining
for proteolytically cleaved PARP (marker for apoptosis) com-
pared to control, estradiol, or BSO-treated groups (Figure 6d).
Overall, these data show that BSO either alone or in combina-
tion with estradiol, reduces tumor growth by inhibiting prolifer-
ation and increasing apoptosis.
Discussion
In the current study, we investigated whether suppression of
the antioxidant glutathione by BSO has the ability to sensitize
antihormone resistant MCF-7:2A breast cancer cells to estra-
diol-induced apoptosis. Our results showed that glutathione
levels and the enzymes involved in its synthesis, glutathione
synthetase and glutathione peroxidase, were significantly ele-
vated in MCF-7:2A cells compared to parental MCF-7 cells
and that suppression of glutathione by BSO sensitized these
cells to estrogen-induced apoptosis in vitro and in vivo. The
BSO-mediated estradiol-induced apoptosis was associated
with a marked decrease in the expression of antiapoptotic Bcl-
2 and Bcl-xL proteins and a significant increase in proapop-
totic Bax protein. It is worth noting that high-dose estrogen
was generally considered the endocrine therapy of choice for
postmenopausal women with breast cancer prior to the intro-
duction of tamoxifen, however, due to undesirable side effects,
the use of high-dose estrogen was largely abandoned [29].
Here, we show that the killing effect of estradiol in antihormone
resistant cells can be achieved at physiological concentrations
when it is combined with non-toxic concentrations of BSO.
Our present findings are consistent with previous studies
which have shown that the cytotoxicity of a number of chemo-
therapeutic drugs, including melphalan [30], doxorubicin [31],
and bleomycin [32], are significantly enhanced when glutath-
ione is depleted by BSO.
An important target of BSO plus estradiol-induced apoptosis
appears to be Bcl-2, whose protein expression was dramati-
cally decreased in MCF-7:2A cells following glutathione
depletion. Previous studies have shown that Bcl-2 functions
as an antioxidant to block apoptosis and that Bcl-2 protein lev-
els and glutathione intracellular concentration is coordinately
regulated with a decrease in either favoring cell death [23,33].
It is believed that one mechanism by which Bcl-2 may function
as an antioxidant is through upregulation of glutathione, lead-
ing to rapid detoxification of reactive oxygen species and inhi-
bition of free radical-mediated mitochondrial damage. Bcl-2
also has the ability to shift the entire cellular redox potential to
a more reduced state, which is independent of its effect on
glutathione levels [33]. It is worth noting that glutathione levels
Figure 5
Activation of c-Jun N-terminal kinase (JNK) signaling pathway in MCF- 7:2A cells in response to buthionine sulfoximine (BSO) and 17β-estra- diol (E2) treatment Activation of c-Jun N-terminal kinase (JNK) signaling pathway in MCF-
7:2A cells in response to buthionine sulfoximine (BSO) and 17β-estra-
diol (E2) treatment. (a) MCF-7 and MCF-7:2A cells were treated with 
ethanol vehicle (control), 1 nM E2 or 100 μM BSO plus E2 for 48 h and 
protein levels of phosphorylated JNK, JNK, phosphorylated c-Jun, and 
c-Jun were analyzed by western blotting. β-Actin was used as a control. 
(b) Inhibition of JNK activation by SP600125 (SP) partially reverses the 
apoptotic effect of BSO and estradiol in MCF-7:2A cells. Cells were 
pretreated with 20 μM SP600125 or vehicle for 24 h, then further incu-
bated for 48 h with 1 nM E2, E2 + 100 μM BSO, 20 μM SP, or E2 + 
BSO + SP and apoptosis was determined by annexin V-propidium 
iodide (PI) staining as described in Materials and methods. Columns, 
mean percentage of apoptotic cells from three independent experi-
ments performed in triplicate; bars, ± standard error of the mean 
(SEM). **, p < 0.001 compared with control (C) cells; ##, p < 0.01 
compared with E2 plus BSO-treated cells.Breast Cancer Research    Vol 10 No 6    Lewis-Wambi et al.
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and Bcl-2 protein expression were significantly elevated in
MCF-7:2A cells compared to parental MCF-7 cells. In phase I
trials [34,35], the concentration of BSO in blood has been
shown to reach 0.5 to 1 mM, whereas, in mice [36,37] the
concentration has been estimated to be 5 to 6 mM following
an in vivo treatment of 4 mmol/kg. In our study, we showed
that 100 μM BSO decreased glutathione concentrations by
approximately 60% after 24 h and that BSO enhanced the
apoptotic effect of estradiol in MCF-7:2A breast cancer cells
as early as 48 h after treatment. Interestingly, treatment with
BSO alone did not cause apoptosis in MCF-7:2A cells, indi-
cating that glutathione depletion alone may not trigger apopto-
sis in these cells. This finding is consistent with previous
studies by Mirkovic et al. [38] which showed that inhibition of
glutathione by BSO did not increase susceptibility of mouse
lymphoma cells to radiation-induced apoptosis even under
conditions where glutathione levels were lowered by 50%.
Other groups have made similar observations using BSO [39].
One possible explanation for this apparent contradiction might
be the fact that BSO does not lower glutathione levels in mito-
chondria as effectively as it does in the cytoplasm [40]. Mito-
chondrial glutathione concentrations are regulated and have
been implicated in apoptotic cell death [41], hence, it would
be of interest to evaluate relative glutathione concentrations in
the mitochondrial matrix of MCF-7:2A cells following treatment
with BSO either alone or in combination with estradiol.
Another possibility could be that cellular thiols other than glu-
tathione may play important roles in regulating apoptosis [39].
The flavoprotein thioredoxin has been shown to be upregu-
lated in several human tumors and is implicated in both cancer
cell growth and apoptotic resistance [42]. However, it is not
known whether Bcl-2 or other apoptotic regulators can influ-
ence the levels of thioredoxin or whether such modulation may
contribute to resistance in human tumor cells.
Apart from Bcl-2, we also found that proapoptotic Bax protein
was markedly increased in MCF-7:2A cells by the combination
of BSO plus estradiol and this induction coincided with a loss
of mitochondrial membrane integrity and cytochrome c
release. Bax is normally found as a monomer in the cytosol of
Figure 6
Buthionine sulfoximine (BSO) inhibits the growth of MCF-7:2A tumors in vivo Buthionine sulfoximine (BSO) inhibits the growth of MCF-7:2A tumors in vivo. Athymic nude mice (4 to 5 weeks old, n = 20) were injected with 
MCF-7:2A breast cancer cells and after 20 days when tumors had reached a mean cross-sectional area of 0.3 cm2, animals were randomized into 4 
groups and were treated with placebo (saline), 17β-estradiol (E2), BSO, or BSO plus E2 for 7 days as described in Materials and methods. BSO (4 
mmol/kg weight) was diluted in saline and was injected intraperitoneally daily. (a) Tumor size was measured everyday and cross-sectional area was 
calculated by multiplying the length (l) by the width (w) by π and dividing the product by 4 (lwπ/4). Data is shown as mean ± standard error of the 
mean (SEM). *, p < 0.05, control group compared with the E2 group; †, p < 0.002 control group compared with BSO group; § p < 0.001 control 
group compared with BSO + E2 group. (b) Microscopy of hematoxylin and eosin (H&E)-stained histological sections of MCF-7:2A tumors treated 
with placebo, E2, BSO, or BSO plus E2. (c) Immunohistochemical analysis of the proliferation marker Ki-67 in MCF-7:2A tumors treated with pla-
cebo, E2, BSO, or BSO plus E2. (d) Paraffin-embedded tumor sections of mice treated with E2, BSO, or BSO plus E2 were immunostained for pro-
teolytically cleaved poly(ADP-ribose) polymerase (PARP), which exists only when cells undergo apoptosis. Three to four tumors per treatment group 
were analyzed.Available online http://breast-cancer-research.com/content/10/6/R104
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non-apoptotic cells and it oligomerizes and translocates to the
outer mitochondrial membrane in response to apoptotic stim-
uli and induces mitochondrial membrane permeabilization and
cytochrome c release [19]. In MCF-7:2A cells, Bax protein
was induced as early as 24 h after BSO plus estradiol treat-
ment (Figure 4) and suppression of Bax expression using
siRNA was able to partially reverse the apoptotic effect of the
combination treatment (data not shown). The induction of Bax
coincided with cytochrome c release from the mitochondria
into the cytosol, which was followed by activation of caspase
7, and PARP cleavage. It is worth noting that pretreatment of
cells with the universal caspase inhibitor z-VAD almost com-
pletely blocked the apoptotic effect of BSO plus estradiol. It is
also worth noting that antiapoptotic Bcl-2 and Bcl-xL proteins
were also markedly decreased in MCF-7:2A cells following the
combination treatment of BSO plus estradiol (Figure 4) and
overexpression of Bcl-xL partially blocked the apoptotic effect
of BSO plus estradiol (data not shown). This finding is impor-
tant because there is evidence that suggests that the ratio
rather than the amount of antiapoptotic vs proapoptotic pro-
teins determines whether apoptosis will proceed [43]. Thus, it
is reasonable to suggest that the apoptotic effect of BSO plus
estradiol is mediated, in part, by the mitochondrial pathway
through their ability to alter the ratio between proapoptotic and
antiapoptotic proteins in target cells.
In addition to the mitochondrial pathway, BSO plus estradiol
appears to induce apoptosis, in part, through activation of the
JNK signaling pathway. JNKs are a group of mitogen-activated
protein kinases (MAPKs) that bind the N-terminal activation
domain of the transcription factor c-Jun and phosphorylate c-
Jun on amino acid residues Ser63 and Ser73 [44]. JNKs are
stimulated by multiple factors including cytokines, DNA-dam-
aging agents, and environmental stresses and are important in
controlling programmed cell death or apoptosis. The inhibition
of JNKs has been shown to enhance chemotherapy-induced
inhibition of tumor cell growth, suggesting that JNKs may pro-
vide a molecular target for the treatment of cancer [44]. We
found that JNK activation (as measured by the increased levels
of phospho-JNK1/2 and the JNK substrate phospho-c-Jun)
correlated well with BSO plus estradiol-induced apoptosis in
MCF-7:2A cells and pharmacologic disruption of this pathway
using the JNK inhibitor SP600125 significantly attenuated this
effect. Previously, Chen and coworkers [45] reported that
BSO enhanced the apoptotic effect of arsenic (As2O3) in
leukemia and lymphoma cells through activation of JNK and
upregulation of death receptor (DR)5 and that inhibition of JNK
by SP600125 decreased DR5 upregulation and apoptotic
induction in U937 leukemia cells treated with arsenic plus
BSO. While the exact mechanism by which JNK promotes
apoptosis is not currently known, the phosphorylation of tran-
scription factors such as c-Jun and p53, as well as pro- and
antiapoptotic Bcl-2 family members [46] has been suggested
to be of importance. It is worth noting that treatment with BSO
plus estradiol markedly increased phosphorylated c-Jun in
MCF-7:2A cells and decreased phosphorylated Bcl-2 in these
cells. These findings thus suggest that BSO plus estradiol
might mediate their apoptotic effect, in part, through activation
of JNK.
Conclusion
We have demonstrated that glutathione depletion by BSO
sensitizes hormone-resistant MCF-7:2A human breast cancer
cells to estradiol-induced apoptosis in vitro and in vivo. This
finding has important clinical implications; particularly for the
use of estrogen deprivation as long-term therapy, and it sug-
gest that, if and when resistance develops, a strategy of treat-
ment with estrogen combined with BSO may be effective in
sensitizing resistant cells to apoptosis. It is worth noting that
recently, Lonning and coworkers [9] reported a 33% complete
response (that is, stable disease) with high dose diethyl-
stilbestrol (DES) in postmenopausal patients with advanced
breast cancer who were heavily pretreated with endocrine
agents. However, 67% of the patients showed partial or no
response [9] so the key to future clinical progress in the treat-
ment of antihormone resistant breast cancer is to improve cur-
rent treatment strategies. We are currently evaluating the
optimal dose of daily estradiol therapy to reverse antihormonal
resistance [4] but the goal is to enhance the estradiol-induced
apoptotic response. The present findings suggest that BSO is
indeed capable of enhancing the apoptotic effect of estradiol
in antihormone resistant breast cancer cells. It is worth noting
that a phase I study of BSO administered with the anticancer
drug melphalan showed that continuous-infusion of BSO was
relatively nontoxic and resulted in depletion of tumor glutath-
ione [35,47]. Thus it is possible that future clinical studies of
BSO infusions combined with low dose estrogen hold the
promise of improving disease control for patients with antihor-
mone resistant ER-positive metastatic breast cancer.
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